BackNeurocrine Biosciences Overview
Neurocrine Biosciences, Inc.

Neurocrine Biosciences Target Price

See Neurocrine Biosciences's analyst price targets ($200) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$156.49

Average Target Price

$204.7530.8% upside

20 analysts in the last 4 months

High: $230 | Low: $170

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-03Wedbush$19424% upsideOpen
2026-08-03H.C. WainwrightAndrew Fein$21537.4% upsideOpen
2026-08-03Canaccord GenuitySumant Kulkarni$21034.2% upsideOpen
2026-07-31Morgan Stanley$19625.2% upsideOpen
2026-07-31Deutsche BankDavid Hoang$19021.4% upsideOpen
2026-07-31Needham$20430.4% upsideOpen
2026-07-31Piper SandlerGAAP EPS$21034.2% upsideOpen
2026-07-31Robert W. BairdBrian Skorney$22543.8% upsideOpen
2026-07-31Guggenheim$22241.9% upsideOpen
2026-07-21Guggenheim$20027.8% upsideOpen
2026-07-17Wells Fargo$20027.8% upsideOpen
2026-07-13Truist Financial$20027.8% upsideOpen
2026-07-13BMO Capital$1708.6% upsideOpen
2026-07-13Wedbush$18518.2% upsideOpen
2026-07-07RBC CapitalBrian Abrahams$19524.6% upsideOpen
2026-06-30UBS$20832.9% upsideOpen
2026-06-02Goldman SachsCorinne Johnson$21336.1% upsideOpen
2026-05-21BernsteinJeffrey Walch$22141.2% upsideOpen
2026-05-06Oppenheimer$23047% upsideOpen
2026-05-06Piper Sandler$20732.3% upsideOpen
2026-04-06Oppenheimer$22040.6% upsideOpen
2026-03-10Cantor FitzgeraldJosh Schimmer$19524.6% upsideOpen
2026-02-23Wolfe Research$1602.2% upsideOpen
2026-02-17Truist FinancialDanielle Brill$14010.5% downsideOpen
2026-02-12Needham$18518.2% upsideOpen
2026-02-12RBC Capital$17713.1% upsideOpen
2026-02-12Wedbush$1513.5% downsideOpen
2026-02-12Morgan Stanley$17310.6% upsideOpen
2026-02-12H.C. Wainwright$19222.7% upsideOpen
2026-01-23UBS$17813.7% upsideOpen
2026-01-08Truist Financial$1698% upsideOpen
2026-01-08Morgan Stanley$17511.8% upsideOpen
2026-01-05UBSAshwani Verma$18820.1% upsideOpen
2025-12-17H.C. Wainwright$19826.5% upsideOpen
2025-12-11Stifel Nicolaus$18820.1% upsideOpen
2025-12-08RBC Capital$18015% upsideOpen
2025-10-29Truist FinancialDanielle Brill$1729.9% upsideOpen
2025-10-29UBS$18316.9% upsideOpen
2025-10-29RBC Capital$1602.2% upsideOpen
2025-10-29Mizuho Securities$1466.7% downsideOpen
2025-10-29Stifel NicolausPaul Matteis$18316.9% upsideOpen
2025-10-29BMO Capital$1476.1% downsideOpen
2025-10-29NeedhamAmi Fadia$18417.6% upsideOpen
2025-10-29Piper Sandler$17914.4% upsideOpen
2025-10-29JefferiesAkash Tewari$17411.2% upsideOpen
2025-10-20Morgan Stanley$1687.4% upsideOpen
2025-10-09UBSAshwani Verma$19524.6% upsideOpen
2025-07-31Guggenheim$17511.8% upsideOpen
2025-04-28Canaccord Genuity$1581% upsideOpen
2025-04-22H.C. WainwrightAndrew Fein$1687.4% upsideOpen

Neurocrine Biosciences (NBIX) FAQ

Neurocrine Biosciences's target price stands at $200. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $200 for NBIX implies 30.8% upside versus today's price ($156.49). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Neurocrine Biosciences's target price evolved across reporting periods, while the comparison chart places NBIX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Neurocrine Biosciences's reading of $200 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.